Beckermann B M, Kallifatidis G, Groth A, Frommhold D, Apel A, Mattern J, Salnikov A V, Moldenhauer G, Wagner W, Diehlmann A, Saffrich R, Schubert M, Ho A D, Giese N, Büchler M W, Friess H, Büchler P, Herr I
Molecular OncoSurgery Group, Department of General Surgery, University of Heidelberg and German Cancer Research Center, Heidelberg, Germany.
Br J Cancer. 2008 Aug 19;99(4):622-31. doi: 10.1038/sj.bjc.6604508. Epub 2008 Jul 29.
Little is known about the factors that enable the mobilisation of human mesenchymal stem cells (MSC) from the bone marrow into the blood stream and their recruitment to and retention in the tumour. We found specific migration of MSC towards growth factors present in pancreatic tumours, such as PDGF, EGF, VEGF and specific inhibitors Glivec, Erbitux and Avastin interfered with migration. Within a few hours, MSC migrated into spheroids consisting of pancreatic cancer cells, fibroblasts and endothelial cells as measured by time-lapse microscopy. Supernatant from subconfluent MSC increased sprouting of HUVEC due to VEGF production by MSC itself as demonstrated by RT-PCR and ELISA. Only few MSCs were differentiated into endothelial cells in vitro, whereas in vivo differentiation was not observed. Lentiviral GFP-marked MSCs, injected in nude mice xenografted with orthotopic pancreatic tumours, preferentially migrated into the tumours as observed by FACS analysis of green fluorescent cells. By immunofluorescence and intravital microscopic studies, we found the interaction of MSC with the endothelium of blood vessels. Mesenchymal stem cells supported tumour angiogenesis in vivo, that is CD31(+) vessel density was increased after the transfer of MSC compared with siVEGF-MSC. Our data demonstrate the migration of MSC toward tumour vessels and suggest a supportive role in angiogenesis.
关于促使人间充质干细胞(MSC)从骨髓动员至血流以及它们被招募到肿瘤并在肿瘤中滞留的因素,目前所知甚少。我们发现MSC会特异性地向胰腺肿瘤中存在的生长因子迁移,如血小板衍生生长因子(PDGF)、表皮生长因子(EGF)、血管内皮生长因子(VEGF),而特异性抑制剂格列卫、爱必妥和阿瓦斯丁会干扰迁移。通过延时显微镜观察发现,在数小时内,MSC迁移到了由胰腺癌细胞、成纤维细胞和内皮细胞组成的球体中。如逆转录聚合酶链反应(RT-PCR)和酶联免疫吸附测定(ELISA)所示,亚汇合的MSC的上清液由于MSC自身产生VEGF而增加了人脐静脉内皮细胞(HUVEC)的芽生。在体外,只有少数MSC分化为内皮细胞,而在体内未观察到分化现象。通过对绿色荧光细胞进行荧光激活细胞分选(FACS)分析观察到,将慢病毒绿色荧光蛋白(GFP)标记的MSC注射到原位胰腺肿瘤异种移植的裸鼠体内后,它们优先迁移到肿瘤中。通过免疫荧光和活体显微镜研究,我们发现了MSC与血管内皮的相互作用。间充质干细胞在体内支持肿瘤血管生成,也就是说,与注射小干扰RNA-VEGF的MSC(siVEGF-MSC)相比,注射MSC后CD31(+)血管密度增加。我们的数据证明了MSC向肿瘤血管的迁移,并提示其在血管生成中起支持作用。